Researchers compared the effectiveness of 3 biologics for moderate to severe asthma in an observational study and found superior improvement with dupilumab. Dupilumab was associated with higher ...
In short: The US Food and Drug Administration has approved the first medication to help reduce multiple food allergy reactions. The drug is used in Australia to treat asthma, hives and sinus ...
INCHEON, South Korea, Dec. 1, 2025 /PRNewswire/ -- Celltrion, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved a new presentation of OMLYCLO® (omalizumab-igec), the first ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Findings showed equivalent efficacy in change from baseline in weekly itch severity score between omalizumab-igec 300mg and Xolair 300mg. The Food and Drug Administration (FDA) has approved Omlyclo ® ...
PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC (“Kashiv” or the “Company”) today announced that it has entered into a licensing and supply agreement with CRISTÁLIA, one of the leading ...
Intracellular histamine content of basophils did not distinguish among rapid, delayed, and late or no responses to omalizumab in patients with chronic spontaneous urticaria (CSU), nor did it predict ...
Objectives: To describe allergic asthma and allergic rhinitis pathophysiology and review the pharmacologic, pharmacokinetic, pharmacodynamic, efficacy, and safety data for omalizumab. Methods: MEDLINE ...
This Journal feature begins with a case vignette that includes a therapeutic recommendation. A discussion of the clinical problem and the mechanism of benefit of this form of therapy follows. Major ...
In a recent study published in The New England Journal of Medicine, a group of researchers evaluated the efficacy and safety of omalizumab as a standalone treatment in increasing the allergen ...
Food allergies are common and are associated with substantial morbidity; the only approved treatment is oral immunotherapy for peanut allergy. In this trial, we assessed whether omalizumab, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results